Organoid Models and Next-Generation Sequencing for Bone Marrow and Related Disorders

Abstract

Challenges to the musculoskeletal system negatively impact the quality of life of people suffering from them, leading to pain, a decline in mobility, genetic alterations, and potential disorders. The bone marrow (BM) forms an integral part of the musculoskeletal system responsible for erythropoiesis and optimal survival of the various immune and stem cells within the BM. However, due to its dynamic and complex three-dimensional (3D) structure, replicating the BM physiologically in traditional two-dimensional (2D) cell culture settings is often challenging, giving rise to the need for 3D in vitro models to better dissect the BM and its regeneration. Several researchers globally have been investigating various approaches to define an appropriate 3D model for their research. Organoids are novel preclinical models that provide a 3D platform for several tissues and have been analysed using next-generation sequencing (NGS) to identify new molecular pathways at the genetic level. The 3D in vitro models and organoids are increasingly considered important platforms for precision medicine. This review outlines the current knowledge of organoid and 3D in vitro models for the BM. We also discuss different types of 3D models and which may be more adaptable for the BM. Finally, we critically review the NGS techniques used for such models and the future combination of these techniques.

Cell Culture Model Evolution and Its Impact on Improving Therapy Efficiency in Lung Cancer

“…Microfluidic technology offers unique opportunities for various diagnostic applications, including infectious disease detection, biomarker monitoring, or the possibility of combining with next-generation sequencing as futuristic genetic analysis [161]. This technology has the advantage that all analytical steps, such as sample preparation, mixing, and detection, are integrated into a single platform.…”

New Therapeutic Perspectives in Prostate Cancer: Patient-Derived Organoids and Patient-Derived Xenograft Models in Precision Medicine

“…Since, in clinical practice, the time between diagnosis, possible surgery, and/or treatment decision is approximately two to three weeks, "avatar" models should be established as quickly as possible. With this time frame available, PDOs have emerged as an effective ex vivo molecule-and drug-screening tool for therapy decisions [44,94]. Numerous studies have highlighted the ability of PDOs to predict responses to clinical treatment in matched patients, even deciding to change therapy in time before the onset of drug resistance [93,94].…”

“…With this time frame available, PDOs have emerged as an effective ex vivo molecule-and drug-screening tool for therapy decisions [44,94]. Numerous studies have highlighted the ability of PDOs to predict responses to clinical treatment in matched patients, even deciding to change therapy in time before the onset of drug resistance [93,94].…”

Nanobiotechnology in Bone Tissue Engineering Applications: Recent Advances and Future Perspectives

“…Bone regeneration is a complex and intricate process that requires a specific sequence of events, depending upon the trauma or diseased state [24]. Thus, the intricacies and the level of complexity involved in bone regeneration and repair makes it extremely challenging to mimic the organ in vitro or ex vivo [25].…”